EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Lymphoid enhancer-binding factor 1 (LEF1): a reliable immunohistochemical predictive marker for WNT-activated medulloblastoma

Manali Ranade, Sridhar Epari, Mamta Gurav, Ayushi Sahay, Prakash Shetty, Maya Prasad, Tejpal Gupta, Girish Chinnaswamy

Child's Nervous System · 2025

DOI: 10.1007/s00381-025-06872-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Child's Nervous System, 2025. Verfasst von Manali Ranade und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology (Including Molecular Pathology Division), Tata Memorial Hospital & ACTREC, Tata Memorial Centre, Homi Bhabha National Institu…. Hauptthemen laut MEDLINE: Lymphoid Enhancer-Binding Factor 1, Medulloblastoma, Cerebellar Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Advanced Centre for Treatment, Research and Education in Cancer (ACTREC) - Khargar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AIM: To evaluate lymphoid enhancer-binding factor 1 (LEF1) as an immunohistochemical marker for WNT-activated medulloblastoma (WNT-MB). MATERIALS AND METHODS: Medulloblastomas (MB) diagnosed between January 2022 and April 2024, that were molecularly grouped by gene expression profiling and in which LEF1 immunohistochemistry was available formed the study cohort. RESULTS: A of total 151 cases, comprising 40 (26.49%) WNT-activated, 45 (29.80%) SHH-activated, and 66 (43.71%) non-WNT/non-SHH (group 3: 21, group 4: 34, and NOS, i.e. overlapping between group 3 and group 4: 11) formed the study cohort. Age- range was 1-41 years (median: 9 years; interquartile- range: 5-17 years), 118 (78.15%) patients were ≤ 18 years of age, and 33 (21.85%) patients had > 18 years age. LEF1 immunostaining was diffuse (≥ 50% tumour cells) in 32 cases, focal (1-49% tumour cells) in 11 cases, and negative in 108 cases. Diffuse LEF1 staining was observed only in WNT-MB. Focal LEF1 staining was observed in 20% (8/40) of WNT-MB and 6.67% (3/45) of SHH-activated MBs. All 66 non-WNT/non-SHH MB were negative for LEF1. Diffuse (> 50%) LEF1 immunostaining had 100% positive predictive value, 100% specificity and 80% sensitivity for detecting WNT-MB. CONCLUSION: Diffuse LEF1 immunostaining is a reliable and faster method for identifying WNT-activated molecular group of MB.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoid Enhancer-Binding Factor 1MedulloblastomaCerebellar NeoplasmsBiomarkers, TumorWnt ProteinsHumansAdolescentChildFemaleMaleChild, PreschoolInfantYoung AdultAdultImmunohistochemistryPredictive Value of TestsCohort Studies

Stichwörter der Autor:innen

Lymphoid enhancer-binding factor 1 (LEF1)MedulloblastomaWNT activated

Substanzen

Lymphoid Enhancer-Binding Factor 1LEF1 protein, humanBiomarkers, TumorWnt Proteins

Autor:innen und Institutionen

  • Department of Pathology (Including Molecular Pathology Division), Tata Memorial Hospital & ACTREC, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India.
  • Department of Pathology (Including Molecular Pathology Division), Tata Memorial Hospital & ACTREC, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India. sridhep@gmail.com.
  • Department of Surgical Oncology (Neurosurgery Division), Tata Memorial Hospital & ACTREC, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India.
  • Department of Paediatric Oncology, Tata Memorial Hospital & ACTREC, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India.
  • Department of Radiation Oncology, Tata Memorial Hospital & ACTREC, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India.

Förderung

  • Advanced Centre for Treatment, Research and Education in Cancer (ACTREC) - Khargar

Zitieren

APA

Ranade, M., Epari, S., Gurav, M., Sahay, A., Shetty, P., Prasad, M., Gupta, T., & Chinnaswamy, G. (2025). Lymphoid enhancer-binding factor 1 (LEF1): a reliable immunohistochemical predictive marker for WNT-activated medulloblastoma. Child's Nervous System. https://doi.org/10.1007/s00381-025-06872-8

Vancouver

Ranade M, Epari S, Gurav M, Sahay A, Shetty P, Prasad M, et al. Lymphoid enhancer-binding factor 1 (LEF1): a reliable immunohistochemical predictive marker for WNT-activated medulloblastoma. Child's Nervous System. 2025. doi:10.1007/s00381-025-06872-8

BibTeX
@article{Ranade2025,
  author = {Ranade, Manali and Epari, Sridhar and Gurav, Mamta and Sahay, Ayushi and Shetty, Prakash and Prasad, Maya and Gupta, Tejpal and Chinnaswamy, Girish},
  title = {Lymphoid enhancer-binding factor 1 (LEF1): a reliable immunohistochemical predictive marker for WNT-activated medulloblastoma},
  journal = {Child's Nervous System},
  year = {2025},
  doi = {10.1007/s00381-025-06872-8}
}
Kostenlos starten →